poisar

Stocks · News reference

Wells Fargo Maintains Overweight on Abbott Laboratories, Raises Price Target to $112

Jul 17, 2026, 2:28 PMBenzinga Newsdesk

Wells Fargo analyst Larry Biegelsen maintains Abbott Laboratories (NYSE:ABT) with a Overweight and raises the price target from $109 to $112.

Read original sourceMore stocks news

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

ABT
Source
benzinga
Observed
Jul 17, 2026, 2:28 PM
Checked
Jul 17, 2026, 2:28 PM
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Aug 27, 2026, 5:00 PMDelveinsight

    Global Blood-Based Biomarkers Market to Witness Upsurge in Growth at a CAGR of ~9% by 2034 | DelveInsight

    The global blood-based biomarkers market is projected to grow from USD 8.5 billion in 2025 to USD 18.5 billion by 2034, driven by increasing demand for non-invasive diagnostics, rising chronic disease prevalence, and advances in genomics and liquid biopsy technologies. North America leads with 44% market share, while Asia-Pacific shows fastest growth. Key players include Roche, Abbott, Siemens Healthineers, and Thermo Fisher Scientific.

    Read original at globenewswire-inc
    RHHBYABTTMODGXLH
  2. Aug 27, 2026, 3:00 PMSns Insider

    Laboratory Informatics Market to Grow from USD 4.08 Billion in 2025 to USD 6.69 Billion by 2035, at a CAGR of 5.06% - SNS Insider

    The global laboratory informatics market is projected to grow at a CAGR of 5.06% from 2025 to 2035, driven by increased data processing demands, regulatory compliance requirements, and adoption of cloud-native solutions and AI-driven analytics. North America leads with 42.55% market share, while Asia-Pacific is the fastest-growing region. Services and LIMS products dominate, with cloud delivery and electronic lab notebooks showing the strongest growth rates.

    Read original at globenewswire-inc
    TMOAABTWATDHR
  4. Aug 26, 2026, 11:57 AMResearchandmarkets.Com

    Atrial Fibrillation Treatment Devices Market Trends and Forecast, 2035 | Includes Profiles of Abbott, AtriCure, Boston Scientific, Johnson & Johnson, and Medtronic

    The global atrial fibrillation treatment devices market is expected to grow at a 13.1% CAGR from $9.6 billion in 2026 to $29 billion by 2035, driven by aging populations, rising AF prevalence affecting 50-60 million people worldwide, and increasing adoption of advanced ablation and left atrial appendage closure technologies. Pulsed field ablation is forecast to generate over 60% of market revenue by 2035, while North America will retain approximately 50% of global market share. Asia-Pacific is expected to register the fastest regional growth.

    Read original at globenewswire-inc
    ABTBSXATRCMDTJNJ